Chiral Diaryl Macrocycles for Multi-Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer, pain, neurological diseases, autoimmune diseases, and inflammation lack effective small molecule inhibitors targeting multiple protein tyrosine kinases, such as MET, ALK, ROS1, AXL, TRKs, and JAKs, due to resistance mechanisms and limited selectivity.
Innovation Solution
Development of chiral diaryl macrocyclic compounds with specific structural formulas that act as potent inhibitors of these kinases, offering a desirable pharmaceutical profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current small molecule inhibitors are used to target protein tyrosine kinases, then some kinase activity is inhibited, but resistance mechanisms develop and selectivity is limited
Solution Approach 1:
The chiral diaryl macrocyclic compounds are designed to simultaneously inhibit multiple protein tyrosine kinases including MET, ALK, ROS1, AXL, TRKs, and JAKs. The macrocyclic structure with specific chiral centers and aromatic rings provides a universal binding mode that accommodates diverse kinase targets, enabling one compound to address multiple resistance mechanisms across different kinase pathways.
2Adaptability or versatility
If broad-spectrum kinase inhibition is pursued, then multiple kinase targets are covered, but selectivity and pharmaceutical profile deteriorate
Solution Approach 1:
The compounds incorporate specific local structural features including chiral centers (R or S configuration), aromatic rings, and macrocyclic linkers that create localized high-affinity binding regions. These local quality features within the macrocyclic structure enable selective interaction with conserved residues in the kinase ATP-binding site while maintaining overall selectivity and desirable pharmaceutical properties.
3Ease of manufacture
If simple molecular structures are used, then synthesis is easier, but inhibitory potency and selectivity are insufficient
Solution Approach 1:
The macrocyclic compounds are constructed from modular segments including aromatic rings, chiral centers, and linker regions that can be synthesized separately and then assembled. This segmentation approach maintains relative synthesis simplicity while enabling the complex three-dimensional structure necessary for high inhibitory potency and selectivity against multiple kinases.
Data Source
AI summary
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, of the formula I:pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.